Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST

NCT ID NCT03944304

Completed Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested the chemotherapy drug paclitaxel in 40 patients with advanced or metastatic gastrointestinal stromal tumor (GIST) whose cancer had stopped responding to three standard treatments: imatinib, sunitinib, and regorafenib. The study focused on patients with low levels of a protein called P-glycoprotein, as earlier research suggested paclitaxel might work better in this group. The goal was to see if the drug could control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel (a chemotherapy drug)
What this could lead to: If it works, this could provide a new treatment option for patients with advanced GIST who have run out of standard therapies.
What could go wrong: This is a small, early-phase study (40 participants) with no control group. Previous trials showed limited benefit, and the drug may only help a subset of patients with low P-glycoprotein expression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.